Neurogene Inc.
NGNE
$16.80
-$0.98-5.51%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 40.32% | 52.54% | 30.71% | 10.82% | 7.22% |
| Gross Profit | -40.32% | -43.58% | -30.71% | -10.82% | -7.22% |
| SG&A Expenses | 63.16% | 133.63% | 90.33% | 30.38% | 66.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.74% | 67.19% | 43.30% | 13.78% | 17.07% |
| Operating Income | -45.74% | -59.84% | -43.30% | -13.78% | -17.07% |
| Income Before Tax | -38.69% | -55.92% | -37.98% | 119.44% | -16.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -38.69% | -55.92% | -37.98% | 119.44% | -16.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.69% | -55.92% | -37.98% | 119.44% | -16.17% |
| EBIT | -45.74% | -59.84% | -43.30% | -13.78% | -17.07% |
| EBITDA | -48.52% | -64.08% | -46.14% | -15.46% | -17.88% |
| EPS Basic | 96.35% | 95.91% | 96.46% | 2,284.36% | -1,281.84% |
| Normalized Basic EPS | 96.35% | 95.91% | 96.48% | -482.92% | -1,281.87% |
| EPS Diluted | 96.35% | 95.91% | 96.46% | 2,283.98% | -1,281.84% |
| Normalized Diluted EPS | 96.35% | 95.91% | 96.48% | -482.92% | -1,281.87% |
| Average Basic Shares Outstanding | 3,698.66% | 3,711.36% | 3,798.45% | -80.44% | -91.59% |
| Average Diluted Shares Outstanding | 3,698.66% | 3,711.36% | 3,798.45% | -80.44% | -91.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
